Acumen Pharmaceuticals Inc expected to post a loss of 26 cents a share - Earnings Preview

Acumen Pharmaceuticals

22/03/2024 12:46

* Acumen Pharmaceuticals Inc  ABOS.OQ   ABOS.O  is expected
to show no change in quarterly revenue when it reports 
results on March 26 for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Acumen Pharmaceuticals
Inc is
for a loss of 26 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Acumen
Pharmaceuticals Inc is $14.50​, above​ its last closing price
of $4.33. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.27       -0.27      -0.24     Beat    9.8
 Jun. 30 2023  -0.34       -0.35      -0.28     Beat    19.1
 Mar. 31 2023  -0.35       -0.35      -0.28     Beat    19.1​
 Dec. 31 2022              -0.26      -0.32     Missed  -25.3
 ​​Sep.        -0.19       -0.23      -0.26     Missed  -13.1
 30 2022                                                
 Jun. 30 2022  -0.24       -0.24      -0.25     Missed  -2​
 Mar. 31 2022  -0.17       -0.17      -0.23     Missed  -38.6
 Dec. 31 2021              -0.14      -0.42     Missed  -193
 This summary was machine generated March 22 at 12:46 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)